Press release
Peritoneal Cancer Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Peritoneal cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Peritoneal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Peritoneal cancer Pipeline Report
* In May 2025, Corcept Therapeutics announced a Phase 2 study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
* In May 2025, Imunon conducted a phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
* In May 2025, Merck Sharp & Dohme LLC organized a study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
* DelveInsight's Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Peritoneal Cancer treatment.
* The leading Peritoneal Cancer Companies such as Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others.
* Promising Peritoneal Cancer Pipeline Therapies such as Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel , and others.
Stay ahead with the most recent pipeline outlook for Peritoneal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peritoneal Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Peritoneal Cancer Emerging Drugs Profile
* Masitinib: AB Science
Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib's mechanism of action in peritoneal cancer involves inhibiting tumor growth by targeting specific kinases like KIT and PDGFR, crucial for cancer progression, without causing general toxicity. Currently, the drug is in Phase III stage of its clinical trial for the treatment of peritoneal cancer.
* Azenosertib: Zentalis Pharmaceuticals
Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors, and we have designed Azenosertib to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. Currently, the drug is in Phase II stage of its clinical trial for the treatment of peritoneal cancer.
* IMGN151: ImmunoGen
IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FR). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FR, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. Currently, the drug is in Phase I stage of its clinical trial for the treatment of peritoneal cancer.
The Peritoneal Cancer Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
* Peritoneal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market
Explore groundbreaking therapies and clinical trials in the Peritoneal Cancer Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Peritoneal Cancer Drugs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Peritoneal Cancer Companies
Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others
Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Peritoneal Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Peritoneal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peritoneal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Peritoneal Cancer Pipeline Report
* Coverage- Global
* Peritoneal Cancer Companies- Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma and others.
* Peritoneal Cancer Pipeline Therapies- Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel , and others.
* Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Peritoneal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peritoneal Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Peritoneal cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Peritoneal cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Masitinib: AB Science
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Azenosertib: Zentalis Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* IMGN151: ImmunoGen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Peritoneal cancer Key Companies
* Peritoneal cancer Key Products
* Peritoneal cancer- Unmet Needs
* Peritoneal cancer- Market Drivers and Barriers
* Peritoneal cancer- Future Perspectives and Conclusion
* Peritoneal cancer Analyst Views
* Peritoneal cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peritoneal-cancer-pipeline-appears-robust-with-55-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peritoneal Cancer Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4027002 • Views: …
More Releases from ABNewswire
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced…
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY…
Applications of 5-50mm security camera lens
The application scenarios of 5-50 mm surveillance lenses are primarily categorized according to the variations in field of view resulting from changes in focal length. The specific applications are as follows:
1. Wide-angle range (5-12 mm)
Panoramic monitoring for confined spaces A focal length of 5-8 mm (with a field of view of 60 degrees -90 degrees ) is suitable for enclosed small areas within 5 times 5 meters, such as elevator…
Daniel Smart Manufacturing Empowers Riders with their New Custom Builder Feature …
A leather jacket [https://danielsmartmfg.com/collections/mens-leather-motorcycle-jackets] for a rider is an essential part of their ride, and it makes them feel incomplete without it whenever they hit the road. If you are a biker, you must know what it means. Now imagine you can design your leather jacket your way, which may further enhance your experience on the road. Well, Daniel Smart, a renowned brand in the leather jacket industry, is now…
More Releases for Peritoneal
Global Hemodialysis And Peritoneal Dialysis Market Size by Application, Type, an …
According to Market Research Intellect, the global Hemodialysis And Peritoneal Dialysis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The hemodialysis and peritoneal dialysis market is witnessing steady growth, primarily driven by the rising prevalence…
Global Peritoneal Dialysis Market Size by Application, Type, and Geography: Fore …
According to Market Research Intellect, the global Peritoneal Dialysis market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The peritoneal dialysis market is experiencing consistent growth due to the rising global incidence of chronic kidney disease…
Hemodialysis & Peritoneal Dialysis Market Insights & Forecast 2025
The hemodialysis and peritoneal dialysis market is expected to grow at 6.61% CAGR from 2024 to 2030. It is expected to reach above USD 146.95 Billion by 2030 from USD 82.6 Billion in 2023.
The Hemodialysis and Peritoneal Dialysis Market report offers information on the most recent market trends and advancements. This report highlights the market's main growth prospects and offers suggestions for how market players can take advantage of them.…
Hemodialysis and Peritoneal Dialysis Market
Introduction:
The global hemodialysis and peritoneal dialysis market plays a critical role in treating patients with end-stage renal disease (ESRD) and chronic kidney failure. Both hemodialysis and peritoneal dialysis are life-sustaining treatments designed to perform the kidney's essential function of filtering waste, toxins, and excess fluids from the blood. Hemodialysis uses a machine to clean the blood outside the body, while peritoneal dialysis involves the cleansing process occurring within the abdomen…
Peritoneal Dialysis Market Insights, Forecast to 2030
Peritoneal Dialysis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Peritoneal Dialysis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Continuous Ambulatory Peritoneal Dialysis Bag Market
New Jersey, USA - Global Continuous Ambulatory Peritoneal Dialysis Bag Market provides in-depth information on the market dynamics of the Continuous Ambulatory Peritoneal Dialysis Bag industry, including constraints, development opportunities, drivers, and emerging trends. The research provides an in-depth look at well-known organisations, macro and micro market circumstances, and trends. It clarifies the strategic analysis of top rivals, including their partnerships, mergers, new product launches, and joint ventures. It provides…
